Marker Therapeutics Stock Today
| MRKR Stock | USD 1.25 0.05 3.85% |
PerformanceVery Weak
| Odds Of DistressHigh
|
Marker Therapeutics is selling at 1.25 as of the 20th of March 2025; that is 3.85 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.25. Marker Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of March 2014 | Category Healthcare | Classification Health Care |
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. The company has 10.71 M outstanding shares of which 149.81 K shares are now shorted by private and institutional investors with about 1.8 trading days to cover. More on Marker Therapeutics
Moving together with Marker Stock
Moving against Marker Stock
Marker Stock Highlights
| Thematic Idea | Pharmaceutical Products (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsMarker Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Marker Therapeutics' financial leverage. It provides some insight into what part of Marker Therapeutics' total assets is financed by creditors.
| |||||
Marker Therapeutics (MRKR) is traded on NASDAQ Exchange in USA. It is located in 9350 Kirby Drive, Houston, TX, United States, 77054 and employs 8 people. Marker Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.92 M. Marker Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 10.71 M outstanding shares of which 149.81 K shares are now shorted by private and institutional investors with about 1.8 trading days to cover.
Marker Therapeutics currently holds about 18.08 M in cash with (16.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22.
Check Marker Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Marker Therapeutics is $13.92 Million. 30% of Marker Therapeutics outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Marker Ownership Details
Marker Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Invst Llc | 2024-12-31 | 20.2 K | |
| Creative Planning Inc | 2024-12-31 | 17.3 K | |
| Blackrock Inc | 2024-12-31 | 16.6 K | |
| Engineers Gate Manager Lp | 2024-12-31 | 16.4 K | |
| Millennium Management Llc | 2024-12-31 | 16.1 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 15.9 K | |
| Matrix Asset Advisors Inc | 2024-12-31 | 15 K | |
| Bank Of America Corp | 2024-12-31 | 3.2 K | |
| Tower Research Capital Llc | 2024-12-31 | 1.3 K | |
| Nea Management Company, Llc | 2024-12-31 | 1.6 M | |
| Alyeska Investment Group, L.p. | 2024-12-31 | 915.6 K |
Marker Therapeutics Historical Income Statement
Marker Stock Against Markets
Marker Therapeutics Corporate Management
| Gerald Garrett | Senior Operations | Profile | |
| Juan MD | COO, CoFounder | Profile | |
| Peter MBA | CEO Pres | Profile | |
| Dr Sr | Senior Virology | Profile | |
| Nadia Agopyan | Senior Affairs | Profile | |
| Monic MD | Chief Officer | Profile |
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.